Grifols, S.A. (GRFS)
$7.46+0.67%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.3B
- Beta
- 1.19
- Div yield
- 1.41%
- P/E (TTM)
- 14.75
- Short % float
- 0.84%
- Days to cover
- 8.7
- SI change
- +105.0%
- 1W
- +2.05%
- 1M
- -2.48%
- vs SPY 1W
- +0.89%
- vs SPY 1M
- -5.48%
Industry peers
FMP comparable companies · ranked by market cap
- ABTSELLAbbott Laboratories$170.4BRECOVERYQ 19$98.49+1.13%
- BDXSELLBecton, Dickinson and Company$50.4BBULLQ 21$182.75+0.55%
- TECHBUYBio-Techne Corporation$11.3BBULLQ 19$72.45+0.01%
- BIOSELLBio-Rad Laboratories, Inc.$9.7BBULLQ 19$360.40+1.60%
- HAEBUYHaemonetics Corporation$5.4BBULLQ 11$119.47-0.65%
- ADMABUYADMA Biologics, Inc.$2.4BRECOVERYQ 9$10.33+0.29%
- MRVIBUYMaravai LifeSciences Holdings, Inc.$2.0BCRISISQ -1$7.21+3.19%
- QDELBUYQuidelOrtho Corporation$846MRECOVERYQ 8$12.41+8.14%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on GRFS?
- LOPJLB’s latest quantitative signal on Grifols, S.A. (GRFS) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is GRFS in?
- Grifols, S.A. (GRFS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Grifols, S.A. (GRFS) do?
- Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunogl…